2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, Hamzavi I, Ganesan A, Picardo M, Thaçi D, Harris J, Bae J, Tsukamoto K, Sinclair R, Pandya A, Sloan A, Yu D, Gandhi K, Vincent M, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal Of The American Academy Of Dermatology 2022, 88: 395-403. PMID: 36370907, DOI: 10.1016/j.jaad.2022.11.005.Peer-Reviewed Original ResearchConceptsNonsegmental vitiligoLoading doseScoring IndexPercent changePhase 2b clinical trialExtension periodPhase 2b trialPrimary efficacy endpointSerious adverse eventsChronic autoimmune disorderDose-dependent trendEfficacy endpointAdverse eventsWeek 24Autoimmune disordersClinical trialsStable vitiligoPatientsVitiligoSignificant differencesTreatmentDoseBaselineTrialsWeeks
2020
Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?
Peterson D, King B. Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? Journal Of The American Academy Of Dermatology 2020, 84: e63-e64. PMID: 32891783, DOI: 10.1016/j.jaad.2020.08.120.Peer-Reviewed Original Research
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis